Award
NIH Reporter #1ZIAAI000327-44
Laboratory And Pre-clinical Studies Of Parainfluenza Viruses
Recipient
National Institute of Allergy and Infectious Diseases (NIAID)
Award Amount
$1,483,918.00
Ceiling
$1,483,918.00
Awarded
April 27, 2024
Identifier
1ZIAAI000327-44
This award supports laboratory and pre-clinical research on parainfluenza viruses to develop and optimize vaccines, including RSV antigen expression and HPIV3 vaccine candidates, with collaborations from NIH and industry partners.
Description
The project involves laboratory and pre-clinical studies of parainfluenza viruses focusing on vaccine development and immunogenicity optimization. It includes using a PIV3-based vector to express RSV antigen for a bivalent vaccine against pediatric viral respiratory pathogens, evaluating strategies to optimize immunogenicity of the RSV F protein, and developing HPIV3 vaccine candidates attenuated by codon-pair deoptimization. Collaborations include the NIH Vaccine Research Center and Codagenix, Inc.